Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study ACTA PSYCHIATRICA SCANDINAVICA Nolen, W. A., Kupka, R. W., Hellemann, G., Frye, M. A., Altshuler, L. L., Leverich, G. S., Suppes, T., Keck, P. E., McElroy, S., Grunze, H., Mintz, J., Post, R. M. 2007; 115 (5): 360-365

Abstract

To compare the efficacy and tolerability of tranylcypromine vs. lamotrigine in bipolar depression not responding to conventional antidepressants.Bipolar depressed patients received open randomized treatment with tranylcypromine or lamotrigine as add-on to a mood stabilizer during 10 weeks. In a second treatment phase, non-responding patients could receive the opposite drug. Outcome criteria were response (measured with CGI-BP and IDS-C), switch into mania, and completion of the study.Only 20 of 70 planned patients were randomized, due to problems with recruitment, and 19 patients received any medication. During the first treatment phase 5/8 patients (62.5%) responded to tranylcypromine without switch into mania, compared with 4/11 patients (36.4%) on lamotrigine with two switches (statistically not significant). Over both treatment phases, 8/10 patients (80%) receiving tranylcypromine completed the study vs. 5/13 (38.5%) on lamotrigine (likelihood 0.02).There still appears to be a role for tranylcypromine in the treatment of refractory bipolar depression. Larger controlled studies are demanded.

View details for DOI 10.1111/j.1600-0447.2007.00993.x

View details for Web of Science ID 000245390100004

View details for PubMedID 17430413